SCHEMBL5586117

SCHEMBL5586117

COc1cc(C)c(Cl)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(NC(C)=O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.42
CHEK1 O14757 2/20 0.42
IKBKB O14920 1/20 0.42
AURKA O14965 1/20 0.42
DCLK1 O15075 1/20 0.42
RPS6KA5 O75582 1/20 0.42
PRKD3 O94806 1/20 0.42
MAP4K4 O95819 1/20 0.42
RET P07949 1/20 0.42
PHKG2 P15735 1/20 0.42
CDK2 P24941 1/20 0.42
FLT4 P35916 1/20 0.42
MAPKAPK2 P49137 1/20 0.42
CLK2 P49760 1/20 0.42
GSK3B P49841 1/20 0.42
IRAK1 P51617 1/20 0.42
RPS6KA3 P51812 1/20 0.42
CSNK1G2 P78368 1/20 0.42
TAOK1 Q7L7X3 1/20 0.42
PIM3 Q86V86 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5593101 0.89 MAPT (0.43) MAPTCHEK1IKBKBAURKADCLK1
SCHEMBL5585966 0.89 MEN1 (0.48) MAPTEPHB4LMNAMEN1KMT2A
SCHEMBL5592903 0.88 MAPT (0.47) MAPTCHEK1IKBKBAURKADCLK1
SCHEMBL5592598 0.86 SMN1; SMN2 (0.48) MAPTMAPK14THRATHRBLMNA
SCHEMBL5585926 0.85 KDR (0.44) MAPTEPHB4MAPK14HCKMAPK12
SCHEMBL5592945 0.82 MAPT (0.50) MAPTCHEK1EPHB4LMNAMEN1
Cyclopropane SCHEMBL9108474 0.82 MEN1 (0.46) MAPTEPHB4THRBLMNAMEN1
SCHEMBL9885353 0.81 MEN1 (0.45) MAPTGSK3BEPHB4MEN1KMT2A
SCHEMBL5959777 0.80 MEN1 (0.45) MAPTEPHB4BRD4THRBMEN1
SCHEMBL5600303 0.80 MEN1 (0.45) MAPTEPHB4THRBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1858879-B1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY GILEAD CONNECTICUT INC (US) 2012-06-06 EP claimed
EP-1858879-A1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY CGI Pharmaceuticals, Inc. (US) 2007-11-28 EP claimed
WO-2006076593-A1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY CGI PHARMACEUTICALS, INC. (US) 2006-07-20 WO claimed
EP-1858879-B1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY GILEAD CONNECTICUT INC (US) 2012-06-06 EP disclosed
EP-2397478-A1 1,3-diaryl substituted ureas as modulators of kinase activity. CGI Pharmaceuticals, Inc. (US) 2011-12-21 EP disclosed
EP-1858879-A1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY CGI Pharmaceuticals, Inc. (US) 2007-11-28 EP disclosed
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity GILEAD CONNECTICUT, INC. 2006-09-07 US disclosed
WO-2006076593-A1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY CGI PHARMACEUTICALS, INC. (US) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity UCK2, CHUK, AXL MAPT 2782/4885CHEK1 46/4885IKBKB 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.